An observational study in Neuropathic Pain and Arteriovenous Fistulae, sponsored by NHS Greater Glasgow and Clyde. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2016-11-11.
Sponsored by NHS Greater Glasgow and Clyde · Observational
Arteriovenous fistulae are artificial connections between the artery and vein in the arm which allow needles to be inserted for haemodialysising patients wit kidney failure. Occasionally severe debilitating pain can arise from these fistulae for which no cause can be found. Such pain can be very difficult to treat. Many commonly used used painkillers are known to cause significant side effects in patients with renal failure (drowsiness, confusion etc.
Qutenza (topical capsaicin 8%) is a new treatment made from chilli peppers which is applied to the skin as a patch and works directly at the nerve endings in the skin to prevent pain. It therefore should not have the systemic side effects of other drugs. It has been demonstrated to be beneficial in other painful conditions for example post-shingles pain and nerve pain from HIV. It has never been used for critical ischaemia before.
We propose to investigate the efficacy of Qutenza in treating patients with end stage renal failure and chronic pain from their fistulae (AVF). We will recruit 20 patients with painful AVF and treat them with Qutenza. We will follow them up for 12 weeks and monitor the change in their pain scores.
1,287 studies on the registry are indexed under Neuralgia; 256 are open to participants now.
This study's planned enrollment of 20 is below the median of 100 across 260 observational studies indexed under Neuralgia.
Browse Neuralgia studies →NHS Greater Glasgow and Clyde is the lead sponsor of 215 studies on the registry; 39 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with end stage renal failure and chronic neuroapthic pain arising fromt heir arteriovenous fistulae
Exclusion Criteria:
Single treatment with Qutenza (topical capsaicin8%) transdermal patch
Drug: Qutenza
Transdermal patch
Also known as: Topical capsaicin 8%
Neuropathic pain
As assessed by Visual Analogue Pain Score
Time frame: 12weeks
Neuropathic pain
As assessed by Visual Analogue Pain Score and Brief Pain Inventory
Time frame: 1 week, 6 weeks
Quality of life
As assessed by EQ-5D
Time frame: 6 weeks, 12 weeks
Safety and tolerability
As assessed by: Number of adverse reactions.
Time frame: 1 week, 6 weeks and 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NHS Greater Glasgow and Clyde